New Results
Monotherapy efficacy of BBB-permeable small molecule activators of PP2A in glioblastoma
Joni Merisaari, Oxana V. Denisova, Milena Doroszko, Vadim Le Joncour, Patrik Johansson, William P.J. Leenders, David B. Kastrinsky, Nilesh Zaware, Goutham Narla, Pirjo Laakkonen, Sven Nelander, Michael Ohlmeyer, View ORCID ProfileJukka Westermarck
doi: https://doi.org/10.1101/777276
Joni Merisaari
1Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
2Institute of Biomedicine, University of Turku, Turku, Finland
Oxana V. Denisova
1Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
Milena Doroszko
3Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden
Vadim Le Joncour
4Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
Patrik Johansson
3Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden
William P.J. Leenders
5Radboud Institute for Molecular Life Sciences, Department of Biochemistry, Nijmegen, The Netherlands
David B. Kastrinsky
6Icahn School of Medicine at Mount Sinai, New York, New York, USA
7Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA
Nilesh Zaware
6Icahn School of Medicine at Mount Sinai, New York, New York, USA
Goutham Narla
8Department of Internal Medicine, Division of Genetic Medicine, University of Michigan, Ann Arbor, MI, USA
Pirjo Laakkonen
4Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
9Helsinki Institute of Life Science – HiLIFE, Laboratory Animal Centre, University of Helsinki, Helsinki, Finland
Sven Nelander
3Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden
Michael Ohlmeyer
6Icahn School of Medicine at Mount Sinai, New York, New York, USA
10Atux Iskay LLC, Plainsboro, NJ, USA
Jukka Westermarck
1Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland
2Institute of Biomedicine, University of Turku, Turku, Finland
Article usage
Posted September 27, 2019.
Monotherapy efficacy of BBB-permeable small molecule activators of PP2A in glioblastoma
Joni Merisaari, Oxana V. Denisova, Milena Doroszko, Vadim Le Joncour, Patrik Johansson, William P.J. Leenders, David B. Kastrinsky, Nilesh Zaware, Goutham Narla, Pirjo Laakkonen, Sven Nelander, Michael Ohlmeyer, Jukka Westermarck
bioRxiv 777276; doi: https://doi.org/10.1101/777276
Monotherapy efficacy of BBB-permeable small molecule activators of PP2A in glioblastoma
Joni Merisaari, Oxana V. Denisova, Milena Doroszko, Vadim Le Joncour, Patrik Johansson, William P.J. Leenders, David B. Kastrinsky, Nilesh Zaware, Goutham Narla, Pirjo Laakkonen, Sven Nelander, Michael Ohlmeyer, Jukka Westermarck
bioRxiv 777276; doi: https://doi.org/10.1101/777276
Subject Area
Subject Areas
- Biochemistry (11739)
- Bioengineering (8750)
- Bioinformatics (29189)
- Biophysics (14967)
- Cancer Biology (12093)
- Cell Biology (17409)
- Clinical Trials (138)
- Developmental Biology (9419)
- Ecology (14178)
- Epidemiology (2067)
- Evolutionary Biology (18301)
- Genetics (12238)
- Genomics (16797)
- Immunology (11865)
- Microbiology (28068)
- Molecular Biology (11583)
- Neuroscience (60953)
- Paleontology (451)
- Pathology (1870)
- Pharmacology and Toxicology (3238)
- Physiology (4957)
- Plant Biology (10425)
- Synthetic Biology (2884)
- Systems Biology (7338)
- Zoology (1651)